These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23111865)

  • 21. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
    Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
    J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychometric assessment of female overactive bladder syndrome and antimuscarinics-related effects.
    Hsiao SM; Liao SC; Chen CH; Chang TC; Lin HH
    Maturitas; 2014 Dec; 79(4):428-34. PubMed ID: 25238744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Psychometric validation of the OAB-V8 and OAB-V3 scales for the screening of patients with probable overactive bladder in the Spanish population].
    Brenes FJ; Angulo JC; Ochayta D; Rejas J; Arumí D; Cañadas A; Lizarraga I
    Med Clin (Barc); 2014 Dec; 143(12):521-9. PubMed ID: 24725856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison study of two lower urinary tract symptoms screening tools in clinical practice: the B-SAQ and OAB-V8 questionnaires.
    Basra RK; Cortes E; Khullar V; Kelleher C
    J Obstet Gynaecol; 2012 Oct; 32(7):666-71. PubMed ID: 22943714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome.
    Yüce T; Dökmeci F; Çetinkaya ŞE
    Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():91-7. PubMed ID: 26720597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-perceived effectiveness and impact on quality of life of solifenacin in combination with an α-blocker in men with overactive bladder in Sweden: a non-interventional study.
    Henningsohn L; Kilany S; Svensson M; Jacobsen JL
    Aging Male; 2017 Dec; 20(4):266-276. PubMed ID: 28787230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Bladder Wall Thickness on the Outcomes of Antimuscarinic Treatment in Women with Overactive Bladder.
    Azab SS; El Sayed O; El Kafoury M
    Urol Int; 2022; 106(3):291-297. PubMed ID: 34915529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of symptom improvement on patients' bother and quality of life in female patients with overactive bladder treated by solifenacin (SET-Q).
    Gotoh M; Kobayashi T; Sogabe K
    Int J Urol; 2014 May; 21(5):505-11. PubMed ID: 24304092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized, open-label, tolterodine-controlled, comparative study of the novel antimuscarinic agent imidafenacin in patients with overactive bladder.
    Pushkar DY; Kasyan GR; Kolontarev KB; Sharvadze GG; Mukhametshina EI
    Neurourol Urodyn; 2019 Jun; 38(5):1313-1321. PubMed ID: 30888691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
    Aparasu RR; Sura S; Earla JR; Shiozawa A; Ng DB; Schermer CR
    Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment.
    Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A
    Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder.
    Cardozo L; Staskin D; Currie B; Wiklund I; Globe D; Signori M; Dmochowski R; MacDiarmid S; Nitti VW; Noblett K
    Int Urogynecol J; 2014 Dec; 25(12):1655-63. PubMed ID: 24859795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women.
    Chughtai B; Forde JC; Buck J; Asfaw T; Lee R; Te AE; Kaplan SA
    Post Reprod Health; 2016 Mar; 22(1):34-40. PubMed ID: 26883688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The real-life management of overactive bladder: Turkish Continence Society multicenter prospective cohort study with short-term outcome.
    Zümrütbas AE; Citgez S; Acar Ö; İzol V; Uzun H; Kabay Ş; Sancak EB; Yazıcı C; Erdogan MS; Tarcan T; Demirkesen O
    Neurourol Urodyn; 2019 Nov; 38(8):2170-2177. PubMed ID: 31338880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of the Overactive Bladder-Bladder Assessment Tool (OAB-BAT): A Potential Alternative to the Standard Bladder Diary for Monitoring OAB Outcomes.
    Chapple C; Kelleher C; Siddiqui E; Andrae DA; Johnson N; Payne C; Homma Y; Hakimi Z; Evans C; Lyn N; Kopp Z
    Eur Urol Focus; 2021 Sep; 7(5):1176-1183. PubMed ID: 33451958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
    Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S
    Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychometric evaluation of the Overactive Bladder Questionnaire (OAB-q) for measuring quality of life and clinical implications in Greek patients with overactive bladder.
    Kontogiannis S; Athanasopoulos A; Tsagkarakis M; Kontodimopoulos N
    Int Urogynecol J; 2022 Nov; 33(11):3035-3043. PubMed ID: 34626200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
    Swift SE; Siami P; Forero-Schwanhaeuser S
    Clin Drug Investig; 2009; 29(5):305-16. PubMed ID: 19366272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.